RYTM Rhythm Pharmaceuticals Inc

Price (delayed)

$49.8

Market cap

$3.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.63

Enterprise value

$2.98B

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within ...

Highlights
RYTM's revenue has soared by 174% YoY and by 19% QoQ
The gross profit has soared by 168% YoY and by 19% from the previous quarter
Rhythm Pharmaceuticals's equity has plunged by 72% YoY and by 64% from the previous quarter
RYTM's net income has dropped by 52% year-on-year and by 48% since the previous quarter

Key stats

What are the main financial stats of RYTM
Market
Shares outstanding
60.97M
Market cap
$3.04B
Enterprise value
$2.98B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
48.64
Price to sales (P/S)
32.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.46
Earnings
Revenue
$91.93M
EBIT
-$257.25M
EBITDA
-$255.54M
Free cash flow
-$140.47M
Per share
EPS
-$4.63
Free cash flow per share
-$2.34
Book value per share
$1.02
Revenue per share
$1.53
TBVPS
$4.19
Balance sheet
Total assets
$258.65M
Total liabilities
$197.07M
Debt
$1.08M
Equity
$61.58M
Working capital
$181.59M
Liquidity
Debt to equity
0.02
Current ratio
4.35
Quick ratio
3.99
Net debt/EBITDA
0.21
Margins
EBITDA margin
-278%
Gross margin
88.4%
Net margin
-297.9%
Operating margin
-295.6%
Efficiency
Return on assets
-87.3%
Return on equity
-179.3%
Return on invested capital
-140.7%
Return on capital employed
-125.8%
Return on sales
-279.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RYTM stock price

How has the Rhythm Pharmaceuticals stock price performed over time
Intraday
0.04%
1 week
-7.59%
1 month
18.94%
1 year
184.57%
YTD
8.33%
QTD
21.29%

Financial performance

How have Rhythm Pharmaceuticals's revenue and profit performed over time
Revenue
$91.93M
Gross profit
$81.24M
Operating income
-$271.71M
Net income
-$273.87M
Gross margin
88.4%
Net margin
-297.9%
RYTM's revenue has soared by 174% YoY and by 19% QoQ
The gross profit has soared by 168% YoY and by 19% from the previous quarter
Rhythm Pharmaceuticals's operating income has shrunk by 52% YoY and by 47% QoQ
RYTM's net income has dropped by 52% year-on-year and by 48% since the previous quarter

Growth

What is Rhythm Pharmaceuticals's growth rate over time

Valuation

What is Rhythm Pharmaceuticals stock price valuation
P/E
N/A
P/B
48.64
P/S
32.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.46
The EPS has contracted by 45% from the previous quarter and by 39% YoY
RYTM's P/B is 178% above its last 4 quarters average of 17.5
Rhythm Pharmaceuticals's equity has plunged by 72% YoY and by 64% from the previous quarter
RYTM's revenue has soared by 174% YoY and by 19% QoQ
RYTM's price to sales (P/S) is 23% higher than its last 4 quarters average of 26.4

Efficiency

How efficient is Rhythm Pharmaceuticals business performance
The ROE has plunged by 138% YoY and by 87% from the previous quarter
The ROA has plunged by 69% YoY and by 59% from the previous quarter
Rhythm Pharmaceuticals's return on invested capital has shrunk by 59% QoQ and by 37% YoY
The ROS has grown by 45% YoY but it has contracted by 27% from the previous quarter

Dividends

What is RYTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RYTM.

Financial health

How did Rhythm Pharmaceuticals financials performed over time
The total assets is 31% more than the total liabilities
The total liabilities has soared by 57% YoY and by 21% from the previous quarter
The quick ratio has declined by 39% year-on-year and by 24% since the previous quarter
The debt is 98% smaller than the equity
The debt to equity has soared by 100% since the previous quarter and by 100% year-on-year
Rhythm Pharmaceuticals's equity has plunged by 72% YoY and by 64% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.